Eda Cengiz,Roy W Beck
Eda Cengiz
Innovations in diabetes medications and technologies have revolutionized our approach to the management of diabetes. Automated insulin delivery (AID) systems have substantially improved overall glycemia and time-in-range; however, AID syste...
Carol J Levy,Elizabeth Seaquist
Carol J Levy
Achieving optimal glycemic control, preventing acute events, and minimizing the risk of chronic complications while maintaining a high quality of life are the primary goals of effective diabetes management. However, many insulin-treated peo...
Thomas C Blevins,Steve V Edelman
Thomas C Blevins
Despite the known acute and chronic complications associated with suboptimal glycemic control, only approximately 25% of people with type 1 diabetes and type 2 diabetes who are treated with prandial insulin are achieving the American Diabet...
The Potential of Inhaled Insulin Therapy in Overcoming Treatment Barriers in People with Insulin-Treated Diabetes [0.03%]
吸入性胰岛素治疗在克服胰岛素治疗糖尿病患者治疗障碍方面的潜力
Korey K Hood,William H Polonsky
Korey K Hood
Barriers to insulin therapy remain a critical challenge for individuals with insulin-treated diabetes, contributing to suboptimal clinical outcomes. The Afrezza® inhaled insulin system, with Technosphere® insulin (TI), is a promising alte...
Case Reports: Practical Use of Pulmonary Inhaled (Technosphere) Insulin in Type 1 Diabetes, Type 2 Diabetes, and Pregnancy [0.03%]
个例报告：1 型糖尿病、2 型糖尿病和妊娠期使用肺部吸入胰岛素（ Technosphere 胰岛素）的实用方法
Irl B Hirsch,Thomas C Blevins,Amy M Valent et al.
Irl B Hirsch et al.
Limitations in current insulin formulations contribute to suboptimal glycemic control and increased risks of hypoglycemia and hyperglycemia. Afrezza® with Technosphere® inhaled insulin (TI) offers a novel therapeutic option with a rapid p...
Roy W Beck,Satish K Garg,Irl B Hirsch
Roy W Beck
Real-World Incidence of Lung Malignancy and Chronic Obstructive Pulmonary Disease with Inhaled Insulin in People with Diabetes [0.03%]
糖尿病患者使用吸入性胰岛素后实际发生肺癌及慢性阻塞性肺病的发病率研究
Kevin Cowart,Hannah Everich,Francisco Flores et al.
Kevin Cowart et al.
Objective: Inhaled insulin offers an alternative to subcutaneous administration, although concerns remain regarding pulmonary risks. We assessed the real-world safety of inhaled insulin versus rapid-acting analogue (RAA) ...
Association of Continuous Glucose Monitoring Metrics with Incident Diabetic Retinopathy: A Real-World Long-Term Study [0.03%]
持续葡萄糖监测指标与新发糖尿病视网膜病变的关联——一项长期真实世界研究
Tomoki Okuno,Sharon A Macwan,Gregory J Norman et al.
Tomoki Okuno et al.
We analyzed data from 2253 veterans with type 1 (34%) or type 2 (66%) diabetes who initiated Dexcom continuous glucose monitoring (CGM) between 2015 and 2022, all with ≥10 days of data over a 6-month landmark period. CGM data were merged w...
Diagnostic Accuracy of Artificial Intelligence-Enabled Retinal Biomarkers for Detecting Type 2 Diabetes and Prediabetes Among Asian Indians [DART Study] [0.03%]
基于人工智能的视网膜生物标志物检测2型糖尿病和前期的诊断准确性[DART研究]
Soujanya Kaup,Sudeshna Sil Kar,Rodrigo M Carrillo-Larco et al.
Soujanya Kaup et al.
Purpose: To identify retinal microvascular features that distinguish normoglycemia from diabetes mellitus (DM)[Study-1] and prediabetes (PreDM)[Study-2] among Asian Indians using artificial intelligence (AI); evaluate the...
Accuracy of Dexcom One+ in Patients with Diabetes or Stress Hyperglycemia Hospitalized in Cardiac Intensive Care Unit [0.03%]
住院心血管重症监护病房糖尿病或应激性高血糖患者使用Dexcom One+的准确性研究
Jerzy Hohendorff,Barbara Zawislak,Michalina Adamczyk-Hohendorff et al.
Jerzy Hohendorff et al.
Background: Continuous glucose monitoring (CGM) systems may assist in glucose management for patients in the cardiac intensive care unit (CICU). We aimed to assess the accuracy, feasibility, and tolerability of Dexcom One...